Aerpio initiates clinical trial of AKB-9778 for treatment of PAOG
Category: #health  By Pankaj Singh  Date: 2019-06-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

Aerpio initiates clinical trial of AKB-9778 for treatment of PAOG

A US-based pharmaceutical company, Aerpio Pharmaceuticals, Inc., recently announced the initiation of Phase 1b clinical trial of AKB-9778 to develop treatment of PAOG (primary open angle glaucoma), report sources.

For the record, Aerpio Pharmaceuticals is a biopharmaceutical company that design compounds that activate Tie2 for treatment of ocular diseases & complications of diabetes. Tie2 is a central regulator of vascular stability and in patients with diabetes & other conditions, down-regulation of Tie2 has been observed. The down-regulation is caused by activation of 2 inhibitors of Tie2: Ang-2 and VE-PTP. AKB-9778 is the company’s leading compound and is being investigated in topical ocular formulation to determine its potential in treatment of primary open angle glaucoma.

As per sources close to the matter, the Phase 1 study will enroll 4 cohorts of 12 subjects & the study is a double-masked and multiple-ascending dose trial. The subjects will receive a placebo or increasing daily doses of topical ocular formulation of AKB-9778. The main endpoint of the trial is ocular tolerability & safety, with intraocular pressure lowering as the key pharmacodynamic endpoint.

Kevin Peters, M.D. & Chief Scientific Officer of Aerpio Pharmaceuticals was reportedly quoted saying that primary open angle glaucoma is characterized by increased intraocular pressure (IOP) leading to neuroretina and optic nerve anomalies. The only clinical approach shown to slow down or prevent vision loss is by reducing IOP. The conventional outflow pathway that consists of specialized vessel Schlemm’s canal & a trabecular meshwork, controls intraocular pressure and has been identified as the site of increased resistance to aqueous humor outflow in primary open angle glaucoma.

In a recent study on animal models, it has been observed that suitable ocular dosing of AKB-9778 lowers intraocular pressure, through its action on Schlemm’s canal & in two sequential Phase 2 clinical studies, it has been observed that medical administration of AKB-9778 significantly reduced intraocular pressure in ocular normotensive patients.

Based on the data collected, it can be concluded that AKB-9778 could provide a differentiated approach to treating primary open angle glaucoma. The company is looking forward to sharing the results of this study by the end of 2019, Peters added.

Source credits: http://ir.aerpio.com/phoenix.zhtml?c=254540&p=irol-newsArticle&ID=2401008

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Yumanity starts Phase 1 trial of YTX-7739 to treat Parkinson’s disease
Yumanity starts Phase 1 trial of YTX-7739 to treat Parkinson’s disease
By Pankaj Singh

Number of cases where people are affected with neurodegenerative diseases have been growing at a substantial pace. Alzheimer’s disease and Parkinson’s disease are the most common neurodegenerative diseases found across the world. Various ...

AngioDynamics buys Eximo Medical and its 355nm Laser Atherectomy tech
AngioDynamics buys Eximo Medical and its 355nm Laser Atherectomy tech
By Pankaj Singh

Owing to widescale tobacco use, the world is seeing an increased number of cancer and vascular diseases. India alone registers more than 10 million cases of peripheral artery disease on an annual basis. Technology and healthcare enterprises are incre...

Scholar Rock to showcase preclinical, phase 1 clinical data of SRK-015
Scholar Rock to showcase preclinical, phase 1 clinical data of SRK-015
By Pankaj Singh

SMA is a rare genetic disease that typically affects young children. Currently, there is no cure for spinal muscular atrophy (SMA), however, various pharmaceutical firms across the world are working to discover a novel, innovative treatment for the d...